Avid Bioservices Inc (CDMO)

[biopharm]

The primary clinical measure in the study was progression-free survival (PFS), and on this endpoint the combination of nintedanib and docetaxel had a modest effect, delaying progression by three weeks compared to docetaxel and placebo, which was a statistically significant difference.

MD, it is easy to see how big PS Targeting/Bavituximab+Docetaxel truly was in Phase IIb NSCLC and currently will be in Phase III "Sunrise" -- as other drugs have such modest effects and come out with approvals.

-------------------------

IQWiG passes Boehringer lung cancer drug

April 10, 2015

Germany’s cost assessor says it can extend life in some patients, but benefit is ‘minor'

IQWiG is tentatively saying yes to Boehringer's oncology drug Vargatef (nintedanib) in new guidance released this week.

...
..
The German health technology assessor says the treatment can be used in combination with chemotherapy agent docetaxel for patients with advanced non-small cell lung cancer (NSCLC) of the glandular tissue (adenocarcinoma), who have already received chemotherapy.

The German Institute for Quality and Efficiency in Health Care (IQWiG) said in its assessment of the drug that there is an “indication of a minor added benefit” of Vargatef in combination with docetaxel in patients without brain metastases.

https://www.pmlive.com/pharma_news/iqwig_passes_boehringer_lung_cancer_drug_707459